Docoh
Loading...

SRPT Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of the end of 2019, the company has two approved drugs . Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.

Company profile

Ticker
SRPT
Exchange
CEO
Douglas Ingram
Employees
Incorporated
Location
Fiscal year end
Former names
ANTIVIRALS INC, AVI BIOPHARMA INC
SEC CIK
IRS number
930797222

SRPT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

1 Mar 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.51B 1.51B 1.51B 1.51B 1.51B 1.51B
Cash burn (monthly) (positive/no burn) (positive/no burn) 62.83M 54.48M 58.18M (positive/no burn)
Cash used (since last report) n/a n/a 215.73M 187.05M 199.76M n/a
Cash remaining n/a n/a 1.3B 1.32B 1.31B n/a
Runway (months of cash) n/a n/a 20.6 24.3 22.6 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Mar 21 M Kathleen Behrens Common Stock Sell Dispose S No No 85.76 5,000 428.8K 130,517
10 Mar 21 M Kathleen Behrens Common Stock Option exercise Aquire M No No 42.3 5,000 211.5K 135,517
10 Mar 21 M Kathleen Behrens Stock Option Common Stock Option exercise Dispose M No No 42.3 5,000 211.5K 0
8 Mar 21 Hans Lennart Rudolf Wigzell Common Stock Sell Dispose S No No 83.51 10,000 835.1K 16,518
8 Mar 21 Hans Lennart Rudolf Wigzell Common Stock Option exercise Aquire M No No 34.92 10,000 349.2K 26,518
8 Mar 21 Hans Lennart Rudolf Wigzell Stock Option Common Stock Option exercise Dispose M No No 34.92 10,000 349.2K 0
3 Mar 21 Barry Richard Common Stock Grant Aquire A No No 0 2,726 0 3,125,366
3 Mar 21 Barry Richard Stock Option Common Stock Grant Aquire A No No 87.11 5,518 480.67K 5,518
3 Mar 21 M Kathleen Behrens Common Stock Grant Aquire A No No 0 2,726 0 130,517
3 Mar 21 M Kathleen Behrens Stock Option Common Stock Grant Aquire A No No 87.11 5,518 480.67K 5,518

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

88.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 446 404 +10.4%
Opened positions 87 51 +70.6%
Closed positions 45 55 -18.2%
Increased positions 122 131 -6.9%
Reduced positions 156 140 +11.4%
13F shares
Current Prev Q Change
Total value 17.35B 9.92B +74.9%
Total shares 70.24M 70.68M -0.6%
Total puts 3.47M 2.36M +47.1%
Total calls 3.44M 1.99M +73.1%
Total put/call ratio 1.0 1.2 -15.0%
Largest owners
Shares Value Change
Capital Research Global Investors 7.74M $1.32B +15.3%
Vanguard 7.22M $1.23B +1.8%
FMR 6.03M $1.03B -4.9%
BLK Blackrock 5.38M $917.1M -1.4%
JHG Janus Henderson 3.88M $660.76M -1.9%
Jennison Associates 2.43M $413.93M -6.8%
STT State Street 1.86M $316.95M -2.1%
Avoro Capital Advisors 1.75M $298.36M +4.5%
AMP Ameriprise Financial 1.6M $272.4M +3.2%
IVZ Invesco 1.44M $245.74M +31.6%
Largest transactions
Shares Bought/sold Change
Capital Research Global Investors 7.74M +1.03M +15.3%
Sands Capital Management 977.14K -888.33K -47.6%
Adage Capital Partners GP, L.L.C. 300K -550K -64.7%
Norges Bank 467.75K +467.75K NEW
Fred Alger Management 10.64K -405.49K -97.4%
JPM JPMorgan Chase & Co. 754.6K -371.91K -33.0%
IVZ Invesco 1.44M +346.42K +31.6%
FMR 6.03M -309.31K -4.9%
Logos Global Management 0 -275K EXIT
Carillon Tower Advisers 263.3K +263.3K NEW

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Aid, amino, analogized, analogy, Arrowhead, assigned, attack, Azar, Biden, Bratica, brightest, buy, campaign, career, caregiving, Chair, childcare, CIFFREO, codenamed, Codiak, constitutionality, contractor, custody, cut, defraud, depict, depiction, devastate, diagnostic, diminish, distancing, driver, ELEVATE, enjoined, ensue, Estepan, ethnic, ethnicity, expenditure, faithfully, fear, Florida, formulary, Fulcrum, gender, GVP, Hansa, Harbor, hearing, heterogeneity, Ian, infection, intermittent, IP, JAMA, join, Joseph, JSC, lawsuit, leadership, learning, magnitude, mg, mission, mix, Neurology, nonperformance, onsite, pandemic, Pennsylvania, pension, predominant, prioritize, racial, reallocate, RegenX, regenxbio, remote, remotely, representation, resilience, rewarding, Selecta, Shield, spread, standalone, strength, sublicense, sweeping, talent, telehealth, terrorism, tuition, Ultragenyx, unclear, unemployment, unremitted, unwilling, urgent, Vifor, viltepso, visit, widespread, women
Removed: al, arose, Bonney, clinic, constantly, dismissal, doubtful, enzyme, Gilead, Interbank, leasing, LIBOR, line, London, Mahatme, Michael, MidCap, mortgage, motion, North, placebo, plaintiff, producing, putative, rental, revision, revolving, Sandesh, SAR, schema, selection, South, Summit, Tivorsan, trust, underway, utrophin, William